Loading...
•
Jun 30, 2025
Oncology Institute Q2 2025 Earnings Report
The Oncology Institute reported strong second quarter 2025 financial results, driven by significant revenue growth and improved Adjusted EBITDA.
Key Takeaways
The Oncology Institute delivered a strong second quarter in 2025, with consolidated revenue increasing by 21.5% year-over-year to $119.8 million. This growth was primarily fueled by exceptional performance in the pharmacy business, which saw over 40% year-over-year growth, and the addition of over 50,000 new capitated lives. The company also significantly reduced its Adjusted EBITDA loss by 53.1% compared to the prior year, demonstrating improved operational efficiency.
Consolidated revenue increased by 21.5% to $119.8 million in Q2 2025, up from $98.6 million in Q2 2024.
Gross profit rose by 34.4% to $17.5 million in Q2 2025.
Adjusted EBITDA improved significantly, with a loss of $4.1 million in Q2 2025 compared to a loss of $8.7 million in Q2 2024.
The company reaffirmed its full-year 2025 revenue guidance and expects to achieve the higher end of the range, driven by strong pharmacy performance and new contract signings.
Revenue by Segment
Forward Guidance
The Oncology Institute reaffirmed its full-year 2025 guidance, expecting revenue to reach the higher end of the $460 million to $480 million range and projecting Adjusted EBITDA of approximately $(2.5) million to $(3.5) million for Q3 2025.
Positive Outlook
- Company believes it can reach the higher-end of the revenue guidance range for 2025.
- Anticipates Adjusted EBITDA of approximately $(2.5) million to $(3.5) million in the third quarter of 2025, indicating continued improvement.
- Momentum in new contract signings is expected to contribute to future growth.
- Continued strength in the pharmacy business is a key driver for achieving revenue targets.
- Planned expansion into new geographic regions of Florida with a major health plan is expected to double covered lives for this payor.
Challenges Ahead
- Achievement of anticipated results is subject to risks and uncertainties disclosed in SEC filings.
- Outlook does not account for the impact of any unanticipated developments in the business or changes in the operating environment.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...